Results 31 to 40 of about 1,005 (173)

Narcolepsy initially misdiagnosed as schizophrenia: A case report

Sleep Research
Sleep Research, Volume 3, Issue 2, Page 180-184, June 2026.
Feng Daoyi, Liu Xin, Xu Rui, He Lihua
doaj   +2 more sources

(A) Pharmacophore hypothesis using pitolisant as a model molecule and, (B) 2D interaction diagram of molecular docking of pitolisant at HDAC2 binding site.

, 2022
(A) Pharmacophore hypothesis using pitolisant as a model molecule and, (B) 2D interaction diagram of molecular docking of pitolisant at HDAC2 binding site.
Bikash Medhi (3908917), Harvinder Singh (2795035), Ajay Prakash (8688492), Nishant Shekhar (8855216), Anupam Raja (12598318)   +4 more
core   +1 more source

Pitolisant in an Adolescent with Prader-Willi Syndrome

The Journal of Pediatric Pharmacology and Therapeutics, 2021
This case report evaluates the potential benefit of pitolisant in a 15-year-old female with Prader-Willi syndrome, obsessive-compulsive disorder, autism spectrum disorder, and mild intellectual disability. Due to its action on the H3 receptor, it enhances central activity of histaminergic neurons resulting in increased alertness, irrespective of the ...
Stephanie, Pennington, Danielle, Stutzman, Elise, Sannar   +2 more
openaire   +3 more sources

Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study

, 2023
Background: First symptoms of narcolepsy mostly present during childhood. Pharmacological management options in children are limited, also due to approval status.
Lecendreux M., Plazzi G., Kallweit U., Triller A., Lieberich L., Pech de Laclause A., Vandi S., Rezaei R., Pizza F.   +8 more
core   +1 more source

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

In-silico discovery of dual active molecule to restore synaptic wiring against autism spectrum disorder via HDAC2 and H3R inhibition.

PLoS ONE, 2022
Metal-dependent histone deacetylases (HDACs) are essential epigenetic regulators; their molecular and pharmacological roles in medically critical diseases such as neuropsychiatric disorders, neurodegeneration, and cancer are being studied globally. HDAC2'
Anupam Raja, Nishant Shekhar, Harvinder Singh, Ajay Prakash, Bikash Medhi   +4 more
doaj   +3 more sources

Pitolisant: A Review in Narcolepsy with or without Cataplexy

, 2020
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflict of interest: Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content ...
Yvette Lamb (6930427)
core   +1 more source

cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels

Biomolecules, 2023
Chronic infection with hepatitis B virus (HBV) is incurable, as the current therapeutics cannot eliminate its persistent genomic material, cccDNA. Screening systems for cccDNA-targeting therapeutics are unavailable, as low copies of cccDNA in vitro ...
Ee Chee Ren, Nicole Ziyi Zhuo, Zhi Yi Goh, Isabelle Bonne, Benoît Malleret, Hui Ling Ko   +5 more
doaj   +1 more source

Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility

Nature and Science of Sleep, 2020
Jay T Guevarra, Robert Hiensch, Andrew W Varga, David M Rapoport Division of Pulmonary, Critical Care, and Sleep Medicine, Mount Sinai Integrative Sleep Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USACorrespondence: Jay T ...
Guevarra JT, Hiensch R, Varga AW, Rapoport DM   +3 more
doaj  

Substituted Purines as High-Affinity Histamine H₃ Receptor Ligands

Pharmaceuticals, 2022
Continuing with our program to obtain new histamine H3 receptor (H3R) ligands, in this work we present the synthesis, H3R affinity and in silico studies of a series of eight new synthetically accessible purine derivatives.
Christian Espinosa-Bustos, Luisa Leitzbach, Tito Añazco, María J. Silva, Andrea del Campo, Alejandro Castro-Alvarez, Holger Stark, Cristian O. Salas   +7 more
doaj   +1 more source